Capecitabine vs CYP2C9 Substrates (High risk)

Interacting Drugs
Capecitabine
vs
CYP2C9 Substrates (High risk)
Security Level
Moderate, Consider therapy modification
Mechanism
CYP2C9 Substrates (High risk): CYP2C9 Inhibitors (Strong) may decrease the metabolism of CYP2C9 Substrates (High risk).
Management
Consider therapy modification

Subscribe for latest updates

Subscribe to our e-mail newsletter to receive updates.

No comments yet.

Post Review about Capecitabine vs CYP2C9 Substrates (High risk)